MentionFoxConexeu Sciences Inc. filed a Form D with the Securities and Exchange Commission on 2026-10-21.
Conexeu Sciences Inc. filed a Form D notice of an exempt securities offering with the SEC on October 21, 2026. The filing reports $1.50M sold. Its industry group is Biotechnology. It names DAVID BOGART (Executive Officer, Director), MILES HARRISON (Executive Officer, Director), AARON FARBERG (Director) (SEC Form D, October 21, 2026).
Sell to companies like Conexeu Sciences Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-10-21 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Conexeu Sciences Inc.
Free to see. No signup.
We'll show it in your MentionFox inbox when Conexeu Sciences Inc. raises, hires or launches. No email unless you switch it on.
Watch Conexeu Sciences Inc. →Get the full cited report on Conexeu Sciences Inc.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Conexeu Sciences Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Conexeu Sciences Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 769 filings in Biotechnology, totalled by week. The dot is this raise, $1.50M, on the same scale — one filing against the whole group's total, so it sits low by construction.
David Bogart is named as Executive Officer and Director on the Form D that Conexeu Sciences Inc. filed with the SEC on 21 October 2026, one of 12 people that filing names.
Miles Harrison is named as Executive Officer and Director on the Form D that Conexeu Sciences Inc. filed with the SEC on 21 October 2026, one of 12 people that filing names.
Aaron Farberg is named as Director on the Form D that Conexeu Sciences Inc. filed with the SEC on 21 October 2026, one of 12 people that filing names.
Stephen Inouye is named as Executive Officer on the Form D that Conexeu Sciences Inc. filed with the SEC on 21 October 2026, one of 12 people that filing names.
Claudia Chavez-Munoz is named as Executive Officer on the Form D that Conexeu Sciences Inc. filed with the SEC on 21 October 2026, one of 12 people that filing names.
Jeff Sharpe is named as Director on the Form D that Conexeu Sciences Inc. filed with the SEC on 21 October 2026, one of 12 people that filing names.
Z Lorenc is named as Director on the Form D that Conexeu Sciences Inc. filed with the SEC on 21 October 2026, one of 12 people that filing names.
Sebastian Purcell is named as Director on the Form D that Conexeu Sciences Inc. filed with the SEC on 21 October 2026, one of 12 people that filing names.
Brian Pilcher is named as Executive Officer on the Form D that Conexeu Sciences Inc. filed with the SEC on 21 October 2026, one of 12 people that filing names.
Andrew Costa is named as Director on the Form D that Conexeu Sciences Inc. filed with the SEC on 21 October 2026, one of 12 people that filing names.
April Burke is named as Director on the Form D that Conexeu Sciences Inc. filed with the SEC on 21 October 2026, one of 12 people that filing names.
Ana Bastiani-Posner is named as Director on the Form D that Conexeu Sciences Inc. filed with the SEC on 21 October 2026, one of 12 people that filing names.
12 people named on the filing — 5 holding an executive role and 7 as directors only.
Named as of the 2026-10-21 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Conexeu Sciences Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Conexeu Sciences Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Conexeu Sciences Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Conexeu Sciences Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Conexeu Sciences Inc.. With no account yet, you sign up free and land on the result.
https://mentionfox.com/funding/conexeu-sciences-inc-form-d-000061